Form 4: UroGen Pharma Director Butitta Acquires 10,000 Stock Options
SEC Form 4
Director Cynthia M Butitta acquired 10,000 stock options in UroGen Pharma Ltd on August 6, 2024.
Summary
- Cynthia M Butitta, a director of UroGen Pharma Ltd, reported a transaction on August 6, 2024.
- Butitta acquired 10,000 stock options with an exercise price of $15.16.
- These options vest in equal quarterly installments over one year, contingent upon continuous service.
- The options expire on August 6, 2034.
- Following the transaction, Butitta directly owns 10,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine transaction. The director's acquisition of stock options could be interpreted as a positive signal, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard Form 4 filing, reflecting a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/06/2024 | Date of transaction: acquisition of stock options. |
| 08/06/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.